8-K: Sanuwave Health Reports Q3 2026 Results Amidst Market Headwinds

Sanuwave Health announced a 24% year-over-year revenue decrease for Q3 2026, reporting an operating loss and a net loss, largely attributed to a proposed CMS rule impacting customer operations and market hesitancy.

Summary

• Sanuwave Health reported Q3 2026 revenues of $8.6 million, a 24% decrease from $11.3 million in Q3 2025.
• The company experienced an operating loss of $1.1 million in Q3 2026, compared to an operating income of $0.9 million in Q3 2025.
• Net loss for Q3 2026 was $1.4 million, a significant shift from a net income of $9.7 million in Q3 2025, which included substantial one-time gains.
• Adjusted EBITDA decreased to $0.7 million in Q3 2026 from $3.2 million in Q3 2025.
• The decline in revenue and system sales is attributed to a proposed CMS rule affecting mobile wound care practitioners and a 'wait and see' market approach.
• Ultramist system sales were 40 units in Q3 2026, down from 155 in Q3 2025 and 82 in Q2 2026.
• Ultramist applicator revenue saw a slight increase of 2% to $6.9 million in Q3 2026.
• Cash and cash equivalents stood at $6.6 million as of September 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to a significant revenue decline and shift from operating income to loss, primarily driven by external market factors and regulatory uncertainty.

Positives

• Ultramist applicator revenue increased by 2% to $6.9 million in Q3 2026 compared to the same quarter last year.
• Gross margin remained strong at 77.3% in Q3 2026, only a slight decrease from 77.6% in Q3 2025.
• There was a 14% increase in HOPD (hospital outpatient department) rates for the 97610 code.
• The Q1 status was removed from the 97610 code, allowing it to be billed concurrently with other procedures.
• CMS and the American Medical Association RUC have signaled interest in reviewing the structure of the 97610 code.

Negatives

• Revenue for Q3 2026 was $8.6 million, a 24% decrease from $11.3 million in Q3 2025.
• Operating loss was $1.1 million in Q3 2026, a reversal from an operating income of $0.9 million in Q3 2025.
• Net loss for Q3 2026 was $1.4 million, compared to a net income of $9.7 million in Q3 2025.
• Adjusted EBITDA significantly decreased to $0.7 million in Q3 2026 from $3.2 million in Q3 2025.
• Sales of Ultramist systems dropped to 40 units in Q3 2026 from 155 units in Q3 2025.
• Cash and cash equivalents decreased to $6.6 million from $11.9 million at the end of 2025.
• The company paid out approximately $2.3 million under sales tax voluntary disclosure agreements during the quarter.

Risks

• The proposed CMS rule to maintain skin substitute pricing at 2026 levels for 2027 caused some mobile wound care practitioners to exit operations, impacting customer base.
• Proposed changes to the 97610 code led to a 'wait and see' market approach, significantly affecting system sales.
• The existence of a market for used Ultramist units may have a cannibalizing effect on new system sales.
• Regulatory oversight risks are present.
• The company faces risks related to regaining and maintaining compliance with Nasdaq listing requirements.
• Competition within the wound care market is a factor.
• Anticipated reimbursement levels for advanced wound care products could affect customer behavior and capital budgets.

Future Outlook

The company continues to gain traction in hospitals and other users where cost savings by halting wound progression is the primary concern and sees this as a core opportunity going forward. Management is engaging with CMS and the American Medical Association RUC regarding potential reviews of the 97610 code structure.

Management Comments

• "Q3 was very much the story of the CMS proposed rule. This affected Sanuwave in multiple ways."
• "The proposal to maintain skin substitute pricing at 2026 levels for 2027 caused a number of mobile wound care practitioners, particularly those providing rural home care, to exit some or all of their operations. This affected a number of our customers."
• "The proposed changes to the 97610 code caused our market to take a sort of wait and see approach across the quarter which, in combination with an ongoing market for used Ultramist units had a significant effect on system sales in the quarter."
• "The silver linings in all this were a 14% increase in HOPD (hospital outpatient department) rates for 97610 and a removal of Q1 status from the code which will allow it to be billed at the same time as other procedures rather than being packaged to zero."
• "CMS and the American Medical Association RUC (the group who makes recommendations to CMS on the value of medical procedures) have also both signaled interest in looking at the structure of the 97610 code around issues like the scaling factors for multiple, large, or difficult wounds that are common in other wound care codes. We will seek to encourage and engage with this."
• "Meanwhile, the company continues to gain traction in hospitals and other users in which cost savings by halting wound progression is the primary concern and continues to see this as a core opportunity going forward."

Industry Context

StockSavvy.ai notes that the results are heavily influenced by regulatory uncertainty surrounding CMS proposed rules, which is impacting the broader wound care market, particularly for mobile and rural practitioners. The company's focus on hospitals and cost-saving applications may offer a more stable segment.

Stakeholder Impact

• Shareholders may be concerned by the significant decline in revenue, profitability, and system sales, as well as the shift to an operating loss.
• Customers, particularly mobile wound care practitioners, are impacted by the CMS proposed rule, leading some to exit operations.
• Suppliers may be affected by reduced sales volumes of Ultramist systems.

Next Steps

• A business update conference call will occur on November 11, 2026.
• The company will seek to encourage and engage with CMS and the American Medical Association RUC regarding the structure of the 97610 code.
• Continue to gain traction in hospitals and other users where cost savings by halting wound progression is the primary concern.

Key Dates

Recommendation

The significant revenue decline and shift to an operating loss are concerning. However, the slight increase in applicator revenue, strong gross margins, and positive regulatory developments regarding the 97610 code suggest potential for recovery. The market's reaction to the CMS rule and the company's ability to navigate these challenges will be critical. A 'hold' recommendation reflects the uncertainty and the need for further clarity on the impact of regulatory changes and the company's strategic response.

Keywords

wound care, Ultramist, CMS rule, revenue, operating loss, Adjusted EBITDA, regenerative medicine, medical systems